|
Press Releases |
|
 |
|
Tuesday, June 15, 2021 |
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
Wednesday, June 9, 2021 |
|
エーザイ、第3回「プラチナキャリア・アワード」において特別賞を受賞 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、第3回「プラチナキャリア・アワード」において、特別賞を受賞しましたのでお知らせします。表彰式は2021年6月8日にオンラインのシンポジウムにて行われました。 more info >> |
|
Eisai Receives Special Prize at Platinum Career Award 2021 |
Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021. more info >> |
|
エーザイ、レンボレキサントの最新データを第35回米国睡眠学会年次総会において発表 |
more info >> |
|
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021) |
Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021. more info >> |
|
Tuesday, June 8, 2021 |
|
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM |
Following U.S. Food and Drug Administration's (FDA) accelerated approval of ADUHELMTM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the diseas. more info >> |
|
バイオジェンとエーザイ、ADUHELM(TM)についてアルツハイマー病の病理に作用する初めてかつ唯一の治療薬として米国FDAより迅速承認を取得 |
バイオジェン(Nasdaq: BIIB、CEO:ミシェル・ヴォナッソス、以下 バイオジェン)とエーザイ株式会社(代表執行役CEO:内藤晴夫、以下 エーザイ)は、本日、米国食品医薬品局(FDA)がADUHELM(TM)(一般名:アデュカヌマブ)について、脳内のアミロイドβプラークを減少させることにより、アルツハイマー病(AD)の病理に作用する初めてかつ唯一のAD治療薬として、迅速承認したことをお知らせします。 more info >> |
|
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease |
Biogen and Eisai, Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. more info >> |
|
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib |
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA. more info >> |
|
Wednesday, June 2, 2021 |
|
エーザイ、人事異動(2021年6月1日付)を発表 |
エーザイ株式会社は本日、人事異動(2021年6月1日付)を発表しました。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
大新銀行與香港地球之友攜手呈獻建築及房地產業ESG專題的中小企論壇
Jun 27, 2022 19:02 HKT/SGT
|
|
|
Dah Sing Bank and Friends of the Earth (HK) Jointly Present Property and Construction Industry ESG Forum for SMEs
Jun 27, 2022 19:01 HKT/SGT
|
|
|
玄武云招股中:国内最大智慧CRM服务供应商 核心客户净收入留存率超100%
Jun 27, 2022 17:15 HKT/SGT
|
|
|
玄武雲招股中:国内最大智慧CRM服務供應商 核心客戶净收入留存率超100%
Jun 27, 2022 17:14 HKT/SGT
|
|
|
Novel patching material for bone defects
Jun 27, 2022 17:00 HKT/SGT
|
|
|
Honda、新型「STEP WGN(ステップ ワゴン)」受注状況を発表
Jun 27, 2022 17:00: JST
|
|
|
Aretis Creces Protocol正式發佈 - DeFi 3.0集成DAO
Jun 27, 2022 13:07 HKT/SGT
|
|
|
Aretis Creces Protocol正式发布 - DeFi 3.0集成DAO
Jun 27, 2022 13:06 HKT/SGT
|
|
|
Hektar REIT's ESG Commitment Gets Rewarded with a 4-Star Rating
Jun 27, 2022 12:00: JST
|
|
|
三菱重工、エジプトの大手石油精製会社ANRPCと水素燃焼技術を導入する契約を締結
Jun 27, 2022 12:00: JST
|
|
|
医思健康荣获《机构投资者》2022亚洲区最佳管理团队多个奖项
Jun 27, 2022 11:45 HKT/SGT
|
|
|
醫思健康榮獲《機構投資者》2022亞洲區最佳管理團隊多個獎項
Jun 27, 2022 11:44 HKT/SGT
|
|
|
EC Healthcare Received "Institutional Investor" 2022 Multiple Awards in All-Asia Executive Team Rankings
Jun 27, 2022 11:42 HKT/SGT
|
|
|
Hektar REIT's ESG Commitment Gets Rewarded with a 4-Star Rating
Jun 27, 2022 11:00 HKT/SGT
|
|
|
GR YARIS Rally1 wins African epic with incredible 1-2-3-4 finish
Jun 27, 2022 10:50 JST
|
|
|
|
More News >> |
|
|
|
|
|